Objective. Systemic lupus erythematosus (SLE) has limited monozygotic twin concordance, implying a role for pathogenic factors other than genetic variation, such as epigenetic changes. Using the disease-discordant twin model, we investigated genome-wide DNA methylation changes in sorted CD4+ T cells, monocytes, granulocytes, and B cells in twin pairs with at least 1 SLE-affected twin.
regulatory regions (6) , in the development of autoimmune diseases.
One early large-scale candidate study comparing 5 MZ twins discordant for SLE identified 49 differentially methylated genes in white blood cells and provided the first indication that interferon (IFN)-regulated genes, such as CD9, IFGNR2, and AIM2, are differentially methylated in SLE (7) . Later case-control epigenomewide association studies (EWAS) using 27K and 450K BeadChips showed pronounced DNA methylation changes in type I IFN-regulated genes in CD4+ T cells and naive CD4+ Tcells (8) (9) (10) .
Only 2 EWAS have investigated other cell types and confirmed the presence of cell type-independent DNA methylation changes in IFN-regulated genes in monocytes, B cells (8) , and granulocytes (11) , but these changes have not been thoroughly investigated. The comparison of discordant twins constitutes a powerful study design for investigating epigenetic alterations, because genetic differences can be ruled out in the case of identical twins, while fraternal twins share, on average, 50% of their genetic variation. This may allow for better discerning between genetic and epigenetic determinants in SLE pathogenesis (12) . Selecting the cellular focus in EWAS is essential, because DNA methylation patterns may vary between cell populations (8, 13) . Given the complex pathogenesis of SLE (14) , it is important to study DNA methylation differences between various immune cell subsets, which might help reveal complementary parts of the disease mechanisms.
In the current study, we make use of a well-defined SLE twin cohort (5) to investigate genome-wide DNA methylation changes in SLE-affected twins and their cotwins in all major cellular compartments: CD4+ T cells, monocytes, granulocytes, and B cells. We observed that promoter hypomethylation of IFN-regulated genes, which previously was observed primarily in CD4+ T cells, was pronounced in all cell types studied. There was additional promoter hypermethylation in B cells, which may be of interest for future studies.
PATIENTS AND METHODS
Twin recruitment. All living Danish twins with an SLE diagnosis in the National Patient Register (15) were identified in the Danish Twin Registry (16) using the unique identification number assigned to all Danish residents in the Civil Registration System (17), as previously described (5) . The following 15 twin pairs were included: 6 MZ, 6 same-sex dizygotic (DZss), and 3 opposite-sex dizygotic (DZos) ( Table 1) . Seven of the twins were male (2 MZ, 2 DZss, and 3 DZos). The mean age of the twins at the time of recruitment was 41.1 years (range 23-67 years). Medical records were consulted for information on SLE or other diagnoses, clinical manifestations, medical history, and time since last disease flare. Seventeen twin individuals fulfilled ≥4 American College of Rheumatology classification criteria for SLE (18) , including 1 MZ and 1 DZss SLE-concordant twin pairs. Four cotwins were affected by other autoimmune diseases (Table 1) . Disease activity was evaluated using the SLE Disease Activity Index 2000 (SLEDAI-2K) (19) . Disease flare was defined as a SLEDAI score ≥4. The project was approved by the Danish Scientific Ethics Committee (journal no. H-1-2014-079) and the Danish Data Inspection Board (journal no. . Written informed consent was obtained from all study participants.
Blood preparation, cell isolation, and DNA/RNA extraction. On the same day as sampling, 50 ml of peripheral blood in EDTA was processed using density-gradient centrifugation (Ficoll-Paque Plus; GE Healthcare), and the granulocyte fraction was stored at À80°C. Serial cell sorting was performed on the mononuclear cell fraction, using a RoboSep device (StemCell Technologies) with CD14-positive selection, then CD4-positive selection, and finally B cell enrichment. Cell purity was assessed using the following antibodies: allophycocyanin (APC)-conjugated surface membrane CD3, phycoerythrin (PE)-conjugated CD4, fluorescein isothiocyanate-conjugated CD8, APC-H7-conjugated CD14, V450-C-conjugated CD45 (BD Biosciences), and PE-Cy7-conjugated CD19 (Beckman Coulter), and analyzed using a BD FACSCanto II flow cytometer (BD Biosciences) after overnight fixation with 1% paraformaldehyde. The purity of the granulocyte fraction was >80%. The mean purity of CD14+ monocytes, CD4+ T cells, and CD19+ B cells was 90%, 91%, and 97%, respectively. DNA and RNA were extracted using an AllPrep DNA/RNA/miRNA Universal Kit (Qiagen) and quantified using a NanoDrop 2000 spectrophotometer and a Quant-iT dsDNA Broad-Range Assay Kit (Thermo Fisher Scientific) according to the instructions of the manufacturer. DNA quality control was performed by analyzing DNA size on an agarose gel and polymerase chain reaction amplification of 2 microsatellite markers for sex verification.
DNA methylation analyses using BeadChips and pyrosequencing. Genome-wide DNA methylation patterns were analyzed using an Infinium HumanMethylation450K BeadChip (Illumina), which interrogates DNA methylation on >480,000 CpG sites, as previously described (20) . Normalized and raw data are available at GEO (GEO accession no. GSE110607). Samples were randomized on the BeadChips to avoid batch effect confounding with phenotypic parameters. Bisulfite treatment was performed on 1 lg of DNA using an EpiTect Fast DNA Bisulfite kit (Qiagen). DNA methylation changes were validated by pyrosequencing, which is a quantitative high-resolution technique yielding DNA methylation profiles at single-nucleotide resolution (21) .
Statistical analysis. Raw data from the BeadChips were extracted using Genome Studio (V.2011.1; Illumina) and normalized using the subset quantile normalization pipeline stratified by cell type (22) . CpG sites that did not fulfill the following criteria were excluded from further analysis: P value for signal detection <0.01, detection P value threshold of >90%, no singlenucleotide polymorphisms with a frequency of >5% (European population in the 1000 Genomes Project [23] ) within 50 bp of the probe, and ≥3 successful beads per probe. Nonspecific probes were excluded from further analysis (24) . In the primary analyses, sex chromosomes were filtered out during normalization. Beta values were calculated as the ratio between the signal intensity of methylated CpG sites and the total signal intensity on a scale of 0 to 1. Paired analyses of discordant twins (n = 13 twin pairs) were performed using the nonparametric Wilcoxon signed rank test. P values less than 0.01 were considered significant, and median differential methylation of >7% was considered biologically relevant. Subsequently, we restricted the analyses to probes located in the gene promoter and start regions (TSS200, TSS1500, and the 5 0 -untranslated region [5 0 -UTR] according to the HumanMethylation450K BeadChip annotation file). Differential methylation of known epigenetic regulators in the promoter/start region in discordant twins was identified using a gene list derived from the EpiFactors database (25) .
In paired subset analyses restricted to the promoter/start region, we further compared twins with recent disease flare (<2 years since the last flare; n = 9 SLE-affected twins) with twins in clinical remission (while receiving or not receiving treatment) for ≥2 years (n = 8 SLE-affected twins). Unpaired subset analyses in MZ twins were performed using a Mann-Whitney U test (n = 6 twin pairs). In both subset analyses, the significance level was set to P < 0.05 and a differential methylation level of >7%, due to the low sample number. For subset analyses of female twins only, the normalization process was repeated including the sex chromosomes in order to examine DNA methylation changes on the X chromosome, using P < 0.001 by Mann-Whitney U test and median differential methylation levels of >7% to determine statistical significance (n = 23 twin individuals).
A permutation test was performed in anti-DNA-positive (n = 6) versus anti-DNA negative twins with SLE (n = 11) and in all anti-DNA positive (n = 10) versus anti-DNA-negative individuals (n = 20), using 10,000 permutations. In an additional analysis, we used the iEVORA algorithm to test for increased epigenetic variability by identifying the most variable CpGs between SLE-affected twins and co-twins or healthy co-twins and re-ranking the most differentially variable CpG according to DNA methylation T statistics (26) . A false discovery rate of <0.001 for differentially variable values and an unadjusted P value of 0.05 for the DNA methylation values were considered statistically significant.
Pyrosequencing data were analyzed using the Wilcoxon signed rank test, in which P < 0.05 defined statistical significance. Gene lists for differentially methylated genes in the promoter/ start region with ≥1 differentially methylated probe in the primary paired analyses were submitted to Ingenuity Pathway Analysis (Qiagen), which was used to identify upstream regulators (P < 0.001 by Fisher's exact test) and enriched biologic terms and canonical pathways (statistical significance defined as a Benjamini-Hochberg-corrected P value of <0.05). The same gene lists were used to identify IFN-regulated genes in the Interferome database (interferome.org/) (27) . All statistical analyses were conducted using the computing environment R (V.3.3.1; r-project.org/).
Validation using an independent SLE case-control sample. In order to replicate selected results observed in the twin sample, peripheral blood from 20 SLE patients (mean AE SD SLEDAI score 13.5 AE 4.7) and 20 healthy controls was 
RESULTS
Differential methylation in SLE-discordant twins. First, we examined genome-wide DNA methylation patterns according to cell type in 13 SLE-discordant twin pairs to determine cell type-specific differences. We then investigated DNA methylation changes within the promoter/start region of each gene, which are more likely to have a functional impact on gene expression.
In CD4+ T cells, 176 probes were differentially methylated in twins discordant for SLE, distributed across 48 probes not associated with a gene and 115 genes ( Table 1A , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40422/abstract). Only 9 genes had ≥2 differentially methylated probes in the promoter/start region (7 hypomethylated and 2 hypermethylated) ( Table 2) .
In monocytes, 510 probes distributed across 160 probes not associated with a gene and 327 genes were differentially methylated in SLE-discordant twins (Figure 1B ; see also Supplementary Data). In the promoter/ start region, 136 genes were differentially methylated, of which 53 were hypomethylated (39%) and 83 were hypermethylated (61%) (see Supplementary Table 1B) . Six genes had ≥2 differentially methylated probes in the promoter/start region, 4 of which were hypomethylated and 2 of which were hypermethylated ( Table 2) .
In granulocytes, 393 probes distributed across 123 probes not associated with a gene and 247 genes were differentially methylated in SLE-discordant twins Figure 1 . Numbers of differentially methylated (diff.meth.) genes in 13 twin pairs discordant for systemic lupus erythematosus, according to cell type. A, CD4+ T cells. B, Monocytes. C, Granulocytes. D, B cells. Paired analyses were performed using the nonparametric Wilcoxon signed rank test. P values less than 0.01 were considered significant, and median differential methylation of >7% was considered biologically relevant. Plus symbols represent hypermethylation; minus symbols represent hypomethylation. Table 1C ). Six genes had ≥2 differentially methylated probes in the promoter/start region, of which 3 were hypomethylated and 3 were hypermethylated (Table 2) . In B cells, 2,882 probes distributed across 987 probes not associated with a gene and 1,628 genes were differentially methylated in SLE-affected twins compared with co-twins ( Figure 1D and Supplementary Data, available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40422/abstract). In the promoter/start region, 748 genes were differentially methylated, of which 265 were hypomethylated (35%), 470 were hypermethylated (63%), and 13 showed the presence of both hypomethylated and hypermethylated probes (2%) (see Supplementary Table 1D , http:// onlinelibrary.wiley.com/doi/10.1002/art.40422/abstract). Altogether, ≥2 differentially methylated probes were observed in 77 promoters, of which 24 were hypomethylated (31%), 50 were hypermethylated (65%), and 3 had both hypomethylated and hypermethylated probes (4%) ( Table 2) .
Next, we identified recurrent DNA methylation changes by investigating the degree of overlap between cell subsets, using gene lists from the primary analyses with ≥1 differentially methylated probe in the promoter/start region (see Supplementary Data, http://onlinelibrary.wiley.com/ doi/10.1002/art.40422/abstract). IFI44L and PLSCR1 were hypomethylated in all cell types. There was overlap between 3 cell types for IFITM1, LOXL1, and NLRC5, DTX3L, PARP9, and LGALS3BP, FKBP5, and MX1 (Figure 2A) . B3GALT4 was hypermethylated in 3 cell types, while there was some overlap between hypermethylated genes in monocytes and B cells, e.g., CBFA2T3 and RUNX3 ( Figure 2B) .
IFN-regulated genes. To more thoroughly describe the expected IFN signature, we submitted gene lists from the primary paired analyses of probes located in the promoter/start region to the Interferome database (27) Overlap between CD4+ T cells, monocytes, granulocytes, and B cells for differentially methylated genes with ≥1 differentially methylated probe in the promoter/start region. A, Hypomethylated genes. B, Hypermethlyated genes. Paired analyses were performed using the nonparametric Wilcoxon signed rank test. P values less than 0.01 were considered significant, and median differential methylation of >7% was considered biologically relevant.
There was some, but not complete, overlap between cell types, with 56.5%, 38.9%, 39.4%, and 12.6% of CD4+ T cells, monocytes, granulocytes, and B cells, respectively, sharing IFN-regulated genes with at least 1 other cell type.
Pyrosequencing. To validate results from the arraybased analysis, 14 probes of interest were selected for quantitative measurement of DNA methylation patterns at single-nucleotide resolution, by pyrosequencing (Table 3  and Supplementary Table 2 , available at http://onlinelibrary. wiley.com/doi/10.1002/art.40422/abstract). We evaluated 5 IFN-regulated genes, IFI44L, IFITM1, LGALS3BP, PARP9, and PLSCR1 (examined in all cell types), 3 (Table 3  and Supplementary Table 3) . However, several genes gained statistical significance in specific cell types during pyrosequencing, all of which were differentially methylated in the same direction as in the array-based analysis. For instance, PARP9 was hypomethylated in all cells except granulocytes in the array-based analysis but was hypomethylated in all cell types by pyrosequencing, suggesting that some minor changes are, as expected, less well-detected using 450K BeadChip technology (28) . The largest overall difference between discordant twins was observed in IFI44L in monocytes and granulocytes, with median hypomethylation of À49.3% (P = 0.025) and À42.6% (P = 0.036), respectively ( Figure 3A and Table 3 ). Of the 5 genes that were differentially methylated exclusively in B cells in the array-based analysis, CXCR5, TRAF5, DDR1, MIR146B, and RSAD2 were validated (Table 3) . CXCR5, TRAF5, and DDR1 were hypermethylated ( Figures 3B-D) , while RSAD2 was hypomethylated in all cell types, although to a larger extent in B cells.
In an independent sample of 20 SLE patients and 20 healthy controls, selected results were replicated by pyrosequencing for CXCR5, DDR1, IFI44L, LGALS3BP, PARP9, PLSCR1, and TRAF5. All genes showed statistically significant differential methylation in the same direction as in the twin analyses (Table 3) . Specifically, the observed B cell hypermethylation in SLE-affected twins was validated (see Supplementary Differential methylation according to disease flare history. To investigate whether the observed DNA methylation differences might vary according to disease activity, we compared twins with SLE and a recent disease flare (within the past 2 years; mean 9 months) (n = 9 twins) with twins with SLE in clinical remission (mean age 11 years) (n = 8 twins) in paired analyses restricted to the promoter/start region. The mean SLEDAI score was 2.8 in twins discordant for SLE with a recent flare and 0.75 in the remaining twins at the time of examination. First, we examined overlapping genes between SLE-affected twins with recent flare compared with the remaining SLE-affected twins to identify common denominators between disease activity states. We then analyzed unique differentially methylated genes in twins with SLE who experienced a recent disease flare in order to identify potential flare-related changes.
In CD4+ T cells, 22 differentially methylated genes in the promoter/start region were shared between SLEaffected twins regardless of flare status, including DTX3L, PARP9, IFI44L, and PLSCR1, with more pronounced hypomethylation in twins with recent flare. Unique genes in twins with recent flare included DDX60, EIF2AK2, IFIT5, IFITM1, RSAD2, and STAT1, which were hypomethylated, and DDR1 and PRIC285, which were hypermethylated (see Supplementary Table 4A , http://onlinelibrary.wiley.com/doi/ 10.1002/art.40422/abstract).
In monocytes, 31 genes were differentially methylated in the promoter/start region in twins regardless of flare status. IFITM1 and TACSTD2 showed more pronounced hypomethylation in twins with recent flare. Unique hypomethylated genes in twins with recent flare included IFI44L, LGALS3BP, DTX3L, PARP9, GGT1, and MX1, while hypermethylated genes included B3GALT4 and PRIC285 (Supplementary Table 4B ).
In granulocytes, 34 differentially methylated genes in the promoter/start region were common to all twins regardless of flare status, including LOXL1 and NLRC5. Hypomethylated genes unique to twins with recent flare included IFITM1, LGALS3BP, IFI44L, DTX3L, PARP9, MX1, and RSAD2, while hypermethylated genes included B3GALT4 and PRIC285 (see Supplementary Table 4C , http://onlinelibrary.wiley. com/doi/10.1002/art.40422/abstract).
In B cells, 196 genes were differentially methylated in the promoter/start region in twins regardless of flare status. HOXB6 and RSAD2 showed more pronounced hypomethylation in twins with recent flare, while B3GALT4, DDR1, NFATC1, DTX1, and SGTA displayed more pronounced hypermethylation. Unique hypomethylated genes in twins with recent flare included IFI44L, LGALS3BP, LOXL1, MIR10A, MIR146B, IFITM1, and PLSCR1, while the most hypermethylated gene was FBXO10 (see Supplementary Table 4D ).
Differential methylation in MZ twins. Using unpaired analyses, we compared differentially methylated genes in the promoter/start regions in 6 MZ twin pairs (including 1 concordant twin pair and 2 co-twins affected by systemic sclerosis and autoimmune thyroid disease) with gene lists from the primary paired analyses. In CD4+ T cells, hypomethylated genes in MZ twins with SLE included IFI44L, LOXL1, EIF2AK2, IKZF4, MIR10A, TNK2, TRIM2, and TRIM22, while NOS1 was hypermethylated (see Supplementary Table 5A , available at http:// onlinelibrary.wiley.com/doi/10.1002/art.40422/abstract). In monocytes, hypomethylated genes included NLRC5, CSDE1, DDX60, DTX3L, PARP9, and PRIC285, while hypermethylated genes included SIGLEC7 and PTPRE (see Supplementary Table 5B ). In granulocytes, MX1, DTX3L, PARP9, NLRC5, and GGT1 were hypomethylated in MZ twins with SLE, while the most hypermethylated gene was ZBTB38 (Supplementary Table 5C ). In B cells, hypomethylated genes included IFI44L, DTX3L, PARP9, NLRC5, RSAD2, and USP18, while the most hypermethylated genes included ARPP-21 and NFATC1 (Supplementary Table 5D ).
X-linked methylation. In unpaired analyses of 15 female twins with SLE and 8 healthy female cotwins, the only differentially methylated gene with ≥2 probes on the X chromosome was SCML2 in monocytes, which showed average hypomethylation of 8.6% at 3 probes in the promoter/start region (data not shown).
Anti-DNA antibodies. To examine whether the observed DNA methylation changes could be antibodydriven, a permutation test was performed, showing no relationship between differential methylation and the presence of anti-double-stranded DNA (anti-dsDNA) antibodies (data not shown).
Differential variability. Due to the stochastic nature of DNA methylation changes in cells at risk for pathologic change, we examined differential variability in twins with SLE (n = 17) compared with co-twins (n = 13) to identify loci with disease-specific highly variable DNA methylation patterns that would not have been detected in the main analysis. Of note, IFI44L was highly variable at cg13304609 in the TSS1500 region of CD4+ T cells and B cells, while USP18 was highly variable at cg14293575 in the 5 0 -UTR in monocytes and granulocytes (see Supplementary Table 6 , available at http://onlinelibrary.wiley. com/doi/10.1002/art.40422/abstract). The results were largely unchanged when co-twins with other autoimmune 886 ULFF-MØLLER ET AL diseases were excluded from the analyses (data not shown). Epigenetic regulators. Differential methylation of known epigenetic regulators including DNA methyltransferases and the activation-induced deaminase pathway was examined to determine whether this might help explain the observed findings. There were no genes with multiple probes showing differential DNA methylation, apart from DTX3L in CD4+ T cells (hypomethylated in 3 cell types) and CTBP2 and PRKAG2 hypermethylation in B cells (see Supplementary Table 7 , available at http://onlinelibrary.wiley.com/doi/10.1002/ art.40433/abstract).
Pathway analysis. Upstream regulators were identified using Ingenuity Pathways Analysis software, and included IFN-regulated genes such as IFNL1 in CD4+ T cells (P = ), and TNF (P = 7.6 9 10
À6
). Due to the observed predominance of B cell hypermethylation, we repeated the analyses stratified by methylation state, which revealed that the top upstream regulators of hypermethylated genes in B cells included TNF (P = 2.0 9 10
) and EP300 (P = 5.5 9 10
À5
) (data not shown). In canonical pathway analyses, only the list of hypermethylated genes in B cells showed significant enrichment of pathways after Benjamini-Hochberg correction. The best-supported pathways included thyroid hormone receptor/retinoid X receptor activation (P = 2 9 10 À3 ), role of macrophages, fibroblasts, and endothelial cells in rheumatoid arthritis (RA) (P = 1.9 9 10 À2 ), and NF-jB signaling (P = 1.9 9 10 À2 ) in hypermethylated genes in B cells.
Network analysis identified antimicrobial and inflammatory response (P = 2.1 9 10 À6 ), infectious disease (P = 6.7 9 10 À5 ), and cancer (P = 7.5 9 10 À5 ) as prominent enriched functions in CD4+ T cells; cancer (P = 1.5 9 10 À5 ), hematologic disease (P = 1.5 9 10 À5 ), and immunologic disease (P = 1.5 9 10 À5 ) in monocytes; antimicrobial response (P = 7.5 9 10 À5 ), cancer (P = 8.4 9 10 À4 ), and organismal injury and abnormalities (P = 8.4 9 10
À4
) in granulocytes; and cancer (P = 1.6 9 10 À22 ), organismal injury and abnormalities (P = 1.6 9 10 À22 ), gastrointestinal disease (P = 1.1 9 10 À19 ), and dermatologic disease and conditions (P = 1.5 9 10 À17 ) in B cells. The networks best supported by the data are shown in Supplementary Figure 2, available at http://onlinelibrary.wiley.com/doi/10. 1002/art.40422/abstract.
DISCUSSION
In the current study, we examined genome-wide DNA methylation in sorted CD4+ T cells, monocytes, granulocytes, and B cells from twins discordant for SLE. Hypomethylation of IFN-regulated genes was robust and common to all cell subsets and more pronounced in twins who had experienced a disease flare within the past 2 years. Differential methylation was more widespread in B cells with predominant hypermethylation, with TNF and EP300 being the most important upstream regulators.
Previous EWAS of SLE have mostly focused on CD4+ T cells, demonstrating hypomethylation of IFNregulated genes (8, 9) . Two studies suggested that the IFN signature is also present in monocytes, B cells (8) , and granulocytes (11) , but the current study is the first to show that the IFN signature is common to all major cellular compartments but with limited gene overlap. We further observed that CD4+ T cells actually displayed the fewest DNA methylation changes, followed by granulocytes, monocytes, and B cells.
Previous studies have shown conflicting results regarding the association between disease activity and DNA methylation changes, with some showing more pronounced hypomethylation of IFN-regulated genes in relation to higher disease activity (9, 29) , while others showed no association (8, 10, 30 ). In the current study, all twins had relatively quiescent disease. However, despite clear DNA methylation differences, the IFN signature was much attenuated in twins who had not had any disease flares for at least 2 years (mean age 11 years). This might suggest that the IFN signature is relatively stable but may gradually fade over years.
In the current study, IFI44L and PLSCR1 promoter hypomethylation was common to all investigated cell types. A recent study suggested that IFI44L promoter hypomethylation in peripheral blood mononuclear cells might potentially be valid as a diagnostic biomarker for SLE, distinguishing SLE patients from healthy controls and patients with RA or Sj€ ogren's syndrome (SS) (29) . In 30 longitudinally sampled SLE patients, IFI44L became less hypomethylated during disease remission, in accordance with our findings. However, in a recent EWAS in patients with SS, IFI44L was also shown to be highly demethylated (20, 31) , and in a large gene expression study comparing the IFN signature between SLE, dermatomyositis, polymyositis, RA, and systemic sclerosis, the most overexpressed common genes were IFI44L, IFI44, RSAD2, IFI27, and IFI6 (32). Thus, further studies are needed to elucidate the validity of IFI44L methylation and other IFN-regulated genes as diagnostic biomarkers for SLE, but they might prove to be convincing candidates for biomarkers of disease activity in autoimmune diseases with known IFN overexpression.
The finding of predominant B cell hypermethylation in SLE has not previously been reported. Only one previous EWAS has investigated B cells in SLE alongside CD4+ T cells and monocytes. Absher et al identified an IFN signature with predominant hypomethylation in all cell types, which was the strongest in CD4+ T cells (8) . Reanalysis of this publicly available data (GEO accession no. GSE59250) did not show evidence for the B cell hypermethylation observed in our study. The origin of this discrepancy is currently unclear. One explanation for the more widespread changes observed in B cells might derive from the extensive DNA methylation changes occurring during B cell differentiation, which affects 30% of CpG sites and is primarily related to DNA hypomethylation at later stages of B cell differentiation (33) . Previous SLE studies showed an expansion of memory and plasma B cell compartments at the expense of naive B cells (34) , in which case a more profound hypomethylation would, however, have been expected. Based on our data, it cannot be excluded that the DNA methylation changes observed in B cells represent a compositional change in the B cell population. To investigate this, further B cell subfractionation is required to identify the exact source of the observed B cell hypermethylation in SLE patients. Using 2 orthogonal technologies in the twin as well as the validation sample, we observed that B cells from SLE patients are clearly different from those from healthy controls, suggesting either early and/or defective reprogramming of B cells in SLE patients. Alternatively, the observed B cell hypermethylation may represent aberrant DNA methylation regulation in SLE. The observed B cell hypermethylation was, however, not associated with either the flare history or differential methylation in known epigenetic regulators (except CTBP2 and PRKAG2).
Previous studies have suggested that the observed B cell hypermethylation may not, however, be restricted to SLE. Two independent EWAS in patients with SS showed marked DNA methylation changes in B cells rather than in CD4+ T cells with predominant B cell hypermethylation (20, 31) . The question of whether the same pathogenic pathway is shared between SS and SLE in B cells remains unanswered. However, at least CXCR5, TRAF5, and DDR1 were hypermethylated in B cells from patients with SS and patients with SLE, which might be of pathogenic interest. CXCR5 in particular is down-regulated in the B cells from SLE patients (35) and might play a role in B cell homing to secondary lymphoid organs (36) , while TNF receptor-associated factor 5 (TRAF5) is a signal transducer for CD40 and activates the NF-jB pathway (37) . Discoidin domain receptor 1 is a collagen receptor that appears to play a role in leukocyte migration (38) . Similarly, DNA methylation analysis of CD19+ B cells from treatment-naive patients with RA showed 4 times more hypermethylated CpGs compared with hypomethylated CpGs (82.3% versus 17.7%), while similar numbers of hypermethylated and hypomethylated probes were detected in CD4+ T cells from the same patients, which provides further evidence for B cellspecific hypermethylation in systemic inflammatory autoimmune diseases (39) . Only 1 study analyzing CD19+ B cells in primary SS also analyzed the gene expression patterns in this cell population, and although there was good correlation between hypomethylation and increased gene expression, hypermethylation was not correlated with expression changes (31) . However, expression was analyzed in only a few hypermethylated genes, and thus further investigation is required.
One important upstream regulator of the observed hypermethylated genes in B cells is tumor necrosis factor (TNF), which is a cytokine with paradoxical effects, because it can trigger both proinflammatory and antiinflammatory pathways (40, 41) . The role of TNF in SLE remains controversial (41) , but in several autoimmune diseases, including RA, TNF inhibitors are a wellestablished treatment, which may, however, induce antinuclear antibody and anti-dsDNA antibody production (42) . Rarely, TNF inhibitors may trigger lupus-like disease, which usually improves upon drug withdrawal. The observed B cell hypermethylation of genes downstream of TNF might suggest a novel mechanism for TNF dysregulation in SLE. Other important upstream regulators in B cells included EP300 and CREBBP, which encode p300 and CREB-binding protein, respectively. These are highly homologous transcriptional coactivators with histone acetyl transferase activity, which regulate RNA polymerase IImediated transcription (43) and are among the most commonly mutated tumor suppressor genes in B cell lymphoma (44) . Interestingly, mice with acetyl transferasedeficient p300 specifically in B cells have been shown to exhibit lupus-like disease, with anti-dsDNA antibody production and glomerulonephritis (45) . This might suggest a link between dysregulated DNA methylation and defective histone acetylation in the B cells of patients with SLE.
In the current study, most differentially methylated genes were found in more than 1 cellular subset. Although most cellular subsets were of high purity, the purity of the granulocyte fraction was >80% pure, which could lead to the lack of detection of some very small DNA methylation differences specific to granulocytes. Furthermore, we were not able to correct for differences in immunosuppressive treatment between SLE twins due 888 ULFF-MØLLER ET AL to the small sample size, which may potentially have influenced the results. A strength, however, was that the use of MZ twins cancels out the influence of genetic effects, which suggests that the observed DNA methylation changes in SLE were not merely present due to a specific genotype. Also, we validated some of the major findings in an independent case-control sample. Overall, our data show that there were both common denominators and major differences between immune cell subsets.
In conclusion, in this genome-wide DNA methylation study, we demonstrate that discordant SLE twins have a clear cell type-dependent IFN signature in CD4+ T cells, monocytes, granulocytes, and B cells, which was strongest in SLE twins who had experienced a disease flare within the last 2 years. B cells exhibited more widespread DNA methylation changes with predominant promoter hypermethylation, which is a novel finding that is of potential interest for further studies of SLE pathogenesis.
